Review Article
Advances in Immunotherapy for Glioblastoma Multiforme
Table 2
Representative clinical trials of vaccine therapy in glioma.
| Registration number | New/recurrent/metastatic | Therapy | Number of patients | Phase |
| EGFRvIII vaccine | | | | | NCT01480479 | New | Rindopepimut/GM-CSF | n = 700 | Phase III | NCT00626015 | New | EGFRvIII peptide vaccine, daclizumab | 3 experimental versus 3 control | Pilot | [96] | New | DC vaccine targeting EGFRvIII antigen | n = 12 | Phase I | [38] | New | EGFRvIII peptide vaccine | n = 18 | Phase II | [39] | New | EGFRvIII peptide Vaccine, TMZ | n = 22 | Phase II | [40] | New | Rindopepimut (CDX-110) | n = 65 | Phase II |
| Heat-shock protein (HSP) vaccine | | | | | NCT01814813 | Recurrent | HSPPC-96 C, bevacizumab | | Phase II | [54] | Recurrent | HSPPC-96 vaccine | n = 41 | Phase II | [97] | New | HSP70 vaccine | n = 12 | Pilot |
| Dendritic cell (DC) vaccines | | | | | NCT00846456 | New | DC vaccine against cancer stem cells | n = 11 | Pilot | NCT00068510 | New + recurrent | C vaccine, toll-like receptor agonists | n = 23 | Phase I | NCT00045968 | New | DCVax®-L | n = 300 | Phase III | [98] | New | DC vaccine | n = 10 | Pilot | [99] | New | DC vaccine | n = 8 | Pilot | [100] | New | DC vaccine | n = 5 | Pilot | [101] | Recurrent | DC vaccine | n = 9 | Phase I | [47] | New + recurrent | multi-epitope pulsed DC vaccine | n = 21 | Phase I | [102] | New + recurrent | DC vaccine | n = 17 | Phase I/II |
| Adoptive T-cell therapy | | | | | NCT02209376 | New + recurrent | CAR T-cells to EGFRvIII | n = 12 | Phase I | NCT00693095 | New | CMV-autologous lymphocyte transfer | n = 12 | Phase I | NCT01109095 | Recurrent | CMV-specific cytotoxic T lymphocytes | n = 16 | Phase I | NCT01454596 | Recurrent | CAR T-cells to EGFRvIII | n = 160 | Phase I/II | NCT02208362 | Recurrent + refractory | Enriched T-cells expressing IL13Ra2 | n = 44 | Phase I | [93] | Recurrent | CMV-specific T-cells | n = 19 | Phase I |
|
|